Clinical trials: Braest Cancer
CANCER, BRAEST CANCER
Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer
Experimental population:Advanced first-line HR+, HER2 metastatic breast cancer patients Research endpoint: Main research endpoint: PFS evaluated by researchers (according to RECIST 1.1 standard) Secondary study endpoint…
- Conditions
- CANCER, BRAEST CANCER, Late Frontline
- Trial name
- NCT06495515
- Testing
- Dalpiciclib，Toremifen
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Braest Cancer, Breast Reconstruction
Evaluating the Effectiveness of an Early Exercise Program After Breast Reconstruction
Breast reconstruction is an important step and option after mastectomy and can help improve the quality of life of breast cancer patients.
- Trial name
- NCT06552650
- Testing
- Exercise, Usual Care
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Braest Cancer, Dry Eye
Corneal Changes in Estrogen-Dependent Breast Cancer After Hormonal Treatment
Aromatase inhibitors (AI) therapy is the treatment of choice for estrogen receptor-positive breast cancer (BC). While AIs effectively suppress tumor growth, estrogen deprivation may have negative impacts on the eyes.
- Trial name
- breast cancer (NCT06924229)
- Testing
- Hormonal treatment
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Sohag University